A Phase 4, Open-label Study Evaluating the Safety and Tolerability of Once Daily Rimegepant for Episodic Migraine Prevention (P11-4.008)
This study evaluated long-term safety and tolerability of once daily (QD) rimegepant 75 mg for episodic migraine (EM) prevention.
Authors
- Esther Straghan
- Robert J. Fountaine (ORCID: https://orcid.org/0000-0002-4105-1248)
- Terence Fullerton
- Jeremias Antinew
- Vittorio Loprinzo
Institutions
- Pfizer (United States) (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000212738
- Citations
- 2
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.94